RekrutujeFaza I
Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell non-Hodgkin Lymphomas (CARMEN).
Miasta: WrocławWiek: od 18 latSponsor: Wroclaw Medical University
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza I
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with…
Miasta: Gdańsk, Poznań, WrocławWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza III
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously…
Miasta: Bydgoszcz, Gdańsk, Kraków, Lublin i 6 innych miastWiek: od 18 latSponsor: Regeneron Pharmaceuticals
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With…
Miasta: Gdańsk, Katowice, Kraków, Lublin i 5 innych miastWiek: od 18 latSponsor: Regeneron Pharmaceuticals Inc.
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma…
Miasta: Bydgoszcz, Gdańsk, Katowice, Kraków i 7 innych miastWiek: od 18 latSponsor: Regeneron Pharmaceuticals Inc.
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza I/II
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Miasta: WrocławWiek: do 17.99 latSponsor: F. Hoffmann-La Roche AG
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Miasta: WrocławWiek: od 18 latSponsor: Miltenyi Biomedicine GmbH
RekrutujeFaza I/II
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Miasta: Gdańsk, Gliwice, Kraków, WrocławWiek: od 18 latSponsor: Kartos Therapeutics, Inc.
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II/III
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are…
Miasta: Bydgoszcz, Chorzów, Gdask, Gdańsk i 9 innych miastWiek: od 18 latSponsor: BeOne Medicines AG